Cervarix
STN:BL 125259
Proper Name:Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant
Tradename: Cervarix
Manufacturer: GlaxoSmithKline Biologicals
Indications:
- Prevention of cervical cancer, cervical intraepithelial neoplasia (CIN) grade 2 or worse and adenocarcinoma in situ, and cervical intraepithelial neoplasia (CIN) grade 1, caused by oncogenic human papillomavirus (HPV) types 16 and 18, in females 9 through 25 years of age
Product Information
Supporting Documents
- Approval History, Letters, Reviews, and Related Documents - Cervarix
- Supporting Documents older than three years - Cervarix